1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Norway >
  5. Gnosis Acquires NattoPharma

M&A Deal Summary

Gnosis Acquires NattoPharma

On May 25, 2021, Gnosis acquired life science company NattoPharma

Acquisition Highlights
  • This is Gnosis’ 1st transaction in the Life Science sector.
  • This is Gnosis’ 1st transaction in Norway.

M&A Deal Summary
Date 2021-05-25
Target NattoPharma
Sector Life Science
Buyer(s) Gnosis
Deal Type Add-on Acquisition

Target

NattoPharma

Oslo, Norway
Based in Norway, NattoPharma is a vitamin K2 research and development, offering the only clinically validated K2 as MK-7 on the market: MenaQ7. NattoPharma provides a comprehensive K2 portfolio of both natural fermented and nature-identical synthesis in various dilutions and solubilities, as well as the industry’s first Full Spectrum K2, delivering MK-6, MK-7, and MK-9. The MenaQ7 Solution Platform offers solutions for brand owners to make vitamin K2 available in a broader range of finished product dose forms, opening opportunities to formulate with multiple active ingredients, guided by the experts of the NattoPharma R&D team.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Gnosis

Desio, Italy
Category Company
Founded 1989
Sector Life Science
DESCRIPTION

Gnosis S.p.A. is a biotechnology company specialized in the manufacturing and sales of fermentation raw materials and natural finished products used in the pharmaceutical, nutraceutical, cosmetic, veterinary, and agricultural industries.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Norway M&A 1 of 1
Year: 2021 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal